Author: Sam Honey
Key Contacts: Declan Goodwin and Andrew McGlashan
Biotech is one of the most exciting, and complex, industries you can get into. The UK is a great place to build a life sciences startup, with its mix of world-leading universities, deep investor networks, and strong government support. But before you dive into R&D, clinical trials, or pitching to VCs, there’s one thing every biotech founder needs to get a handle on: regulation.
Getting to Know the UK Biotech Rulebook
The UK biotech landscape covers a huge range: drugs, gene and cell therapies, diagnostics, AI-powered tools, and devices. Unsurprisingly, that means a web of rules and regulators.
At the centre is the Medicines and Healthcare products[SH1] Regulatory Agency (MHRA): the UK’s main health regulator. It oversees clinical trials, drug approvals, medical devices, and even advanced therapies like gene editing or stem cell treatments. Post-Brexit, the UK has mostly kept EU-style standards, but the MHRA is now more agile and startup-friendly. It offers faster drug reviews (some in just 150 days), and has special schemes for breakthrough innovations, like the Innovative Licensing and Access Pathway, which links you up early with regulators, payers, and the NHS.
Beyond the MHRA, there are other regulators depending on your focus:
- Human Tissue Authority: if you’re handling human cells or tissues (e.g. cell therapies or transplantation).
- Health Research Authority (HRA): if you’re running clinical trials in NHS settings, this authority coordinates research ethics approvals.
- Veterinary Medicines Directorate: if you’re working on animal health products.
- Health and Safety Executive (HSE) and the Department for Environment, Food & Rural Affairs: if you’re working with genetically modified organisms. The HSE is also the primary enforcer of workplace safety rules, including those on hazardous substances, accident reporting and general health and safety.
The key takeaway? Figure out who regulates your work early, and engage with them before you build too far ahead.
Clinical Trials, Approvals & Staying on Track
In the UK, starting human trials means getting two green lights: one from the MHRA (called a Clinical Trial Authorisation) and another from an NHS Research Ethics Committee, coordinated through the HRA. Thankfully, the UK is shifting to a single streamlined application process for both, saving valuable time.
The trial process is speeding up too. There’s a new notification route for certain low-risk studies, and a legal overhaul is aiming for 30-day approval timelines. If you’re working on gene or cell therapies, expect extra scrutiny via the Gene Therapy Advisory Committee, but you’ll also get access to expert regulatory advice early in development.
Here’s the part many startups overlook: before anyone uses your product, even in the trial phase, it must be manufactured under Good Manufacturing Practice (GMP) conditions. In practice, that means securing a Manufacturer’s Authorisation for Investigational Medicinal Products if you’re making the therapy yourself. Try to plan for GMP compliance early, as it is mandatory and often a roadblock for fundraising and partnerships.
IP: Protect It or Lose It
In biotech, intellectual property underpins the business. Whether you’re developing a novel therapy, a cutting-edge diagnostic, or a biotech platform, make sure your IP is protected early and properly.
You can file patents through the UK Intellectual Property Office or European Patent Office, but be strategic, especially with the UK no longer part of the Unified Patent Court. And don’t forget: some things in biotech (like methods of treatment) are harder to patent. For more information on biotech intellectual property, please read our articles on its protection[SH2] and exploitation[SH3] .
Data, Ethics & Trust
Working with patient data? Handling genetic material? Then UK GDPR and the Data Protection Act 2018 apply. Clear data policies are essential, especially for clinical trials or building personalised medicine platforms.
Beyond compliance, there’s the ethical side. Investors and the public care about how your company handles sensitive issues. Having an internal ethics policy, or even an advisory board, can show you’re serious about doing biotech the right way.
Be Ready for Regulation
Whether you’re applying for grants or raising a seed round, regulatory readiness matters. Investors want to know that your licenses are in place, your trials are compliant, and your IP is protected. Regulatory risk is business risk, and savvy founders treat it as part of their go-to-market strategy. So, get advice early, build compliance into your roadmap, and don’t be afraid of the regulatory landscape. It’s all part of turning great science into a successful business.
For advice on your commercial contracts, data protection or exploiting and protecting your IP portfolio, please contact our Commercial and Technology team.
